{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:02:15Z","timestamp":1780696935196,"version":"3.54.1"},"reference-count":33,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The Greek Society of Migraine and Headache Patients conducted, in 2020, its second online survey, titled \u201cMigraine in Greece\u20142020\u201d, after publication of the first similar online survey conducted in 2018. To compare the current findings with the corresponding data obtained in 2018, we herein release the second part of results obtained from the 2020 survey on the efficacy of preventive and symptomatic anti-migraine medications and the patients\u2019 reported satisfaction with these treatments. Materials and Methods: We surveyed 2105 migraine patients from all over Greece with the use of a 151-questions specific migraine-focused questionnaire in Greek language, which was distributed through the online research software \u201cSurveyMonkey\u201d. Results: Triptans were mostly used with efficacy for the symptomatic relief of migraine attacks. About 2 of 3 surveyed patients had received various prophylactic oral medications and the majority of them discontinued these prophylactic medications as a result of inefficacy\/safety issues. BoNTA was reported to be effective only when administration was commenced by a trained neurologist\/headache specialist, while our current findings are generally comparable to those obtained in our 2018 pre-COVID-19 survey and the pandemic has not imposed any significant attitudes on migraine therapies and corresponding patients\u2019 satisfaction. Conclusion: Although a market change is anticipated with the evolving widespread use of anti-CGRPs monoclonal antibodies or gepants in the symptomatic and prophylactic treatment of migraine, it is of great interest to review published results of larger longitudinal population-based studies to further ascertain the satisfaction of patients to migraine therapies.<\/jats:p>","DOI":"10.3390\/medicina59010031","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T04:40:39Z","timestamp":1672116039000},"page":"31","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Results of a Web-Based Survey on 2105 Greek Migraine Patients\u2014Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients\u2019 Reported Satisfaction"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-0076","authenticated-orcid":false,"given":"Emmanouil V.","family":"Dermitzakis","sequence":"first","affiliation":[{"name":"Euromedica General Clinic, 54645 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Kouroudi","sequence":"additional","affiliation":[{"name":"Greek Society of Migraine and Headache Patients, 11743 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-7114","authenticated-orcid":false,"given":"Andreas A.","family":"Argyriou","sequence":"additional","affiliation":[{"name":"Neurology Department, Agios Andreas State General Hospital of Patras, 26335 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C.","family":"Spingos","sequence":"additional","affiliation":[{"name":"Corfu Headache Clinic, 49150 Corfu, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Bilias","sequence":"additional","affiliation":[{"name":"Greek Society of Migraine and Headache Patients, 11743 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Vikelis","sequence":"additional","affiliation":[{"name":"Headache Clinic, Mediterraneo Hospital, 16675 Glyfada, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0038-1646946","article-title":"The Global burden of Headache","volume":"38","author":"Saylor","year":"2018","journal-title":"Semin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/head.13688","article-title":"The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort","volume":"60","author":"Schwedt","year":"2020","journal-title":"Headache"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","article-title":"Patients\u2032 preference for migraine preventive therapy","volume":"47","author":"Peres","year":"2007","journal-title":"Headache"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11916-015-0521-0","article-title":"A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine","volume":"19","author":"Starling","year":"2015","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ane.13600","article-title":"Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis","volume":"145","author":"Argyriou","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-018-0918-3","article-title":"Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment","volume":"19","author":"Vikelis","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/14737175.2022.2091435","article-title":"A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine","volume":"22","author":"Argyriou","year":"2022","journal-title":"Expert Rev. Neurother."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Deighton, A.M., Harris, L.A., Johnston, K., Hogan, S., Quaranta, L.A., L\u2032Italien, G., and Coric, V. (2021). The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: A systematic literature review. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02451-x"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1129-2377-15-31","article-title":"The impact of headache in Europe: Principal results of the Eurolight project","volume":"15","author":"Steiner","year":"2014","journal-title":"J. Headache Pain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results","volume":"35","author":"Adams","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/head.13407","article-title":"Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0333102421989630","article-title":"A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences","volume":"41","author":"Constantinidis","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dermitzakis, E.V., Kouroudi, A., Argyriou, A.A., Spingos, K.C., Bilias, K., and Vikelis, M. (2022). Results of a Web-based survey of 2105 Greek migraine patients in 2020: Demographics, clinical characteristics, burden and the effects of the COVID-19 pandemic on the course of migraine. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02968-9"},{"key":"ref_17","first-page":"12","article-title":"Results of an online survey of 1.091 patients with migraine in Greece in 2018. Epidemiological data, treatment options and effectiveness of treatment; the social, economic and emotional impact of the disease","volume":"28","author":"Dermitzakis","year":"2018","journal-title":"\u039d\u03b5\u03c5\u03c1\u03bf\u03bb\u03bf\u03b3\u03af\u03b1"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_19","first-page":"22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J. Manag. Care Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention","volume":"55","author":"Lipton","year":"2015","journal-title":"Headache"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","article-title":"Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache","volume":"51","author":"Couch","year":"2011","journal-title":"Headache"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14737175.2021.1958677","article-title":"Beyond chronic migraine: A systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders","volume":"21","author":"Argyriou","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s10194-017-0813-3","article-title":"Hellenic Headache Society. Patients\u2032 preferences for headache acute and preventive treatment","volume":"18","author":"Mitsikostas","year":"2017","journal-title":"J. Headache Pain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102420941839","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults","volume":"40","author":"Diener","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40122-021-00296-3","article-title":"Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study","volume":"10","author":"Heinze","year":"2021","journal-title":"Pain Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/head.13940","article-title":"Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom","volume":"60","author":"Toptan","year":"2020","journal-title":"Headache"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-020-01106-5","article-title":"Headache medication and the COVID-19 pandemic","volume":"21","author":"MaassenVanDenBrink","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-022-01400-4","article-title":"European Headache Federation School of Advanced Studies (EHF-SAS). Headache onset after vaccination against SARS-CoV-2: A systematic literature review and meta-analysis","volume":"23","author":"Castaldo","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Straburzy\u0144ski, M., Kuca-Warnawin, E., and Waliszewska-Pros\u00f3\u0142, M. (Neurol. Neurochir. Pol., 2022). COVID-19-related headache and innate immune response\u2014A narrative review, Neurol. Neurochir. Pol., ahead of print.","DOI":"10.5603\/PJNNS.a2022.0049"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/03331024211038654","article-title":"Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study","volume":"42","author":"Sekiguchi","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jiph.2021.04.013","article-title":"The unusual course of a migraine attack during COVID-19 infection\u2014Case studies of three patients","volume":"14","author":"Budrewicz","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"fcab169","DOI":"10.1093\/braincomms\/fcab169","article-title":"Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: A multicentre observational cohort study","volume":"3","author":"Heinze","year":"2021","journal-title":"Brain Commun."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:29Z","timestamp":1760147369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["medicina59010031"],"URL":"https:\/\/doi.org\/10.3390\/medicina59010031","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}